Neurocrine Biosciences
NBIX
NBIX
464 hedge funds and large institutions have $10B invested in Neurocrine Biosciences in 2022 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 162 increasing their positions, 159 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 435 → 464 (+29)
5.82% more ownership
Funds ownership: 93.81% → 99.64% (+5.8%)
2% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 159
Holders
464
Holding in Top 10
12
Calls
$35.1M
Puts
$27.4M
Top Buyers
| 1 | +$493M | |
| 2 | +$84.1M | |
| 3 | +$81.7M | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$67.5M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$45.3M |
Top Sellers
| 1 | -$265M | |
| 2 | -$67.5M | |
| 3 | -$66.5M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$64.9M |
| 5 |
DM
Deerfield Management
New York
|
-$53.1M |